Methods for treatment of cognitive decline
Embodiments of the invention relate to methods for treatment of age-related cognitive decline in a patient comprising administering to the patient a low dose of tetrahydrocannabinol (THC), preferably in an amount of 10-400 micrograms (μg). THC may be administered in a variety of routes. Methods for delaying or slowing or reversing the progression of age-related cognitive decline using THC are also disclosed. The aforementioned methods may slow the progression of age-related cognitive decline. The cognitive decline may be in a patient suffering from Mild Cognitive Impairment (MCI) or a patient with no MCI, in which cognitive decline is prevented.
1. A method for treatment of mild cognitive impairment (MCI) in a patient comprising administering to the patient tetrahydrocannabinol (THC) in an amount of 20-400 micrograms (μg), wherein the patient is at least 45 years old, and has not experienced a stroke, traumatic brain injury or an epileptic seizure in the month prior to administration of the THC.
2. The method according to claim 1 , wherein the treatment comprises delaying or slowing the progression of mild cognitive impairment.
3. The method according to claim 1 , wherein the MCI is amnestic MCI.
4. The method according to claim 1 , wherein the THC is administered in an amount between 20 and 100 μg.
5. The method according to claim 1 , wherein the THC is administered in an amount between 20 and 300 μg.
6. The method according to claim 4 , wherein the THC is administered on a daily basis.
7. The method according to claim 4 , wherein the THC is administered at least once per week.
8. The method according to claim 1 , wherein the THC is administered in a pharmaceutical composition comprising at least one excipient.
9. The method according to claim 1 , wherein the THC is administered through a route selected from the group consisting of: topical, systemic, local, intravenous, subcutaneous, intramuscular, inhalation, insufflation, oral, buccal, sublingual, transdermal, nasal, rectal and parenteral routes.
10. The method according to claim 1 , wherein the THC is administered in combination with at least one additional active pharmaceutical agent.
11. The method according to claim 10 , wherein the at least one additional active pharmaceutical agent is a cannabinoid.
12. The method according to claim 11 , wherein the cannabinoid is cannabidiol (CBD).
13. The method according to claim 12 , wherein the CBD is administered in an amount of between 2 and 20 milligrams.
14. The method according to claim 13 , wherein the CBD is administered in an amount of 5 milligrams.
15. A method for the improvement of cognitive functioning in a patient comprising administering to the patient tetrahydrocannabinol (THC) in an amount of 20-400 μg of THC, wherein the patient is at least 45 years old, and has not experienced a stroke, traumatic brain injury or an epileptic seizure in the month prior to administration of the THC.
16. The method according to claim 1 , wherein the THC is administered in an amount of 300-400 μg.
17. The method according to claim 9 , wherein the THC is administered sublingually.
18. The method according to claim 9 , wherein the THC is administered nasally.
19. The method according to claim 15 , wherein the THC is administered in an amount of 300-400 μg.
20. The method according to claim 15 , wherein the THC is administered in a pharmaceutical composition comprising at least one excipient.
21. The method according to claim 15 , wherein the THC is administered through a route selected from the group consisting of: topical, systemic, local, intravenous, subcutaneous, intramuscular, inhalation, insufflation, oral, buccal, sublingual, transdermal, nasal, rectal and parenteral routes.